Costs and effects of long-acting risperidone in comparison to oral atypical and conventional depot formulations for the treatment of patients with schizophrenia in Germany;Kosten und effekte von risperidon in depotform: Vergleich mit oralen atypika und konventionellen depotformulierungen in der therapie von schizophrenie-patienten in Deutschland

Psychopharmakotherapie

Volumn 12, Issue 5, 2005, Pages 183-192

  Möller, Hans Jürgen ^a,b   Laux, Gerd ^a,c   Naber, Dieter ^a,d   Gastpar, Markus Theodor ^a,e   Klosterkötter, Joachim ^a,f   Schmauss, Max ^a,g   Heeg, Bart ^a   Van Gestel, Aukje ^a   Van Hout, Ben ^a,h   Mehnert, Angelika ^a,i  

^a Klinik für Psychiatrie und Psychotherapie ^*

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Bezirksklinikum Gabersee   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Bezirkskrankenhaus Augsburg   (Germany)

^h PHARMERIT INTERNATIONAL   (Netherlands)

ⁱ JANSSEN CILAG GMBH   (Germany)

Author keywords

Conventional depot formulations; Cost analysis; Germany; Long acting injectable risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AGRANULOCYTOSIS; ARTICLE; COHORT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GERMANY; HOSPITAL PATIENT; HUMAN; INJECTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OUTPATIENT; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 27644473617     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. American Psychiatric Association (APA). Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004;161(Suppl.):2.
2. Bestehorn M, Tischer B, Glaser P, Mast O, et al. Repräsentative Studie zur Verteilung schizophrener Patienten auf medizinische Versorgungseinrichtungen in Deutschland. Fortschr Neurol Psychiatr 1999;67:487-92.
3. Bundesverband der Betriebskrankenkassen BKK (Hrsg.). Hauptabteilung Wirtschaft und Statistik. Krankheitsartenstatistik 2001-2002, Essen.
4. Cameron AM, Oram J, Geffen GM, Kavanagh DJ, et al. Working memory correlates of three symptom clusters in schizophrenia. Psychiatry Res 2002;110:49-61.
5. Carpenter W, Buchanan R. Schizophrenia. N Engl J Med 1994;330:681-90.
6. Chue P, Eerdekens M, Augustyns I, Lachaux B, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. 11th Biennial Winter Workshop on Schizophrenia, Davos, 2002.
7. Clade H. Versorgungsforschung. Fallbeispiel Schizophrenie: Hohe soziale Kosten. Günstiges Kosten-Nutzen-Verhältnis innovativer Medikamente der neuen Generation. Dtsch Ärzteblatt 2003;100:28-9A, 1924A-5.
8. Commissie farmaceutische hulp van het college voor zorgverzekeringen. Farmacotherapeutisch Kompas 2002: Medisch farmaceutische voorlichting. College voor zorgverzekeringen, Amstelveen, 2002.
9. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry 2004;161:414-25.
10. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201.
11. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
12. Csernansky JG, Okamoto A. A long-term double-blind comparison of risperidone and haloperidol in stable outpatients with schizophrenia or schizoaffective disorder. Int J Psychopharmacol 2000;3(Suppl. 1):155.
13. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psych 2003;60:553-64.
14. Davis JM, Matalon L, Watanabe MD, Blake L, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741-73.
15. Department of Veterans Affairs Pharmacy Benefits Management. Medical advisory panel and mental health strategic healthcare group. Guideline for atypical antipsychotic use. http: //www.vapbm.org; Stand: August 2004.
16. Department of Veterans Affairs Pharmacy Benefits Management. Medical advisory panel and mental health strategic healthcare group. Risperidone long-acting: Criteria for use. http: //www.vapbm.org; Stand: August 2004.
17. Dolder C, Lacro J, Dunn L, Jeste D. Antipsychotic medication adherence: Is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-8.
18. Editio Cantor Verlag für Medizin und Naturwissenschaften GmbH. Rote Liste, http: //www.rote-liste.de, Januar 2004.
19. Einheitlicher Bewertungsmaßstab (EBM). Köln: Deutscher Ärzteverlag, 2001.
20. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 2003;64(Suppl. 16):10-3.
21. Fritze H, Saß H, Schmauß M. Befragung der Fachgesellschaften durch den Sachverständigenrat für die Konzertierte Aktion im Gesundheitswesen zur Frage von Über-, Unter- und Fehlversorgung. Stellungnahme der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Pulheim, Aachen und Augsburg, 19. Februar 2001.
22. Gesundheitsbericht für Deutschland. Gesundheitsberichterstattung des Bundes/ Statistisches Bundesamt. Stuttgart: Metzler-Poeschel, 1998:214-5.
23. Heeg BM, van Aalst G, van den Arend IJ, Mehnert A, et al. A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia [abstract no. PMHS]. Value Health 2002;5: 515-6.
24. Plus poster presented at the International Society for Pharmacoeconomics and Outcomes Research. 5th Annual European Congress, 2002 November 3-5, Rotterdam, The Netherlands.
25. Heeg BM, van Aalst GD, Mehnert A, van Hout B. Simulating the course of schizophrenia using discrete events modelling. Value Health 2002;5:524.
26. Heres S, Kissling W. Depotneuroleptika - eine veraltete Therapieform? Psychopharmakotherapie 2004;11:11-4.
27. Hogarty GE. Depot neuroleptics: the relevance of psychosocial factors - a United States perspective. J Clin Psychiatry 1984;45:36-42.
28. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res 2002;54:253-64.
29. Kane JM, Leucht S, Carpenter D, Docherty JP. Optimizing pharmacologic treatment of psychotic disorders. Expert consensus guideline series. J Clin Psychiatry 2003;64(Suppl. 12): 5-19.
30. Kassenärztliche Vereinigung Rheinhessen. Modellversuch der Krankenkassen in Rheinland-Pfalz und des Ministeriums für Arbeit, Soziales, Familie und Gesundheit, Rheinland-Pfalz, 2001.
31. Kompetenznetz Schizophrenie. Laien und Betroffene: Krankheitsbild: Verlauf, http: //www.kompetenznetz-schizophrenie.de/ framesets/fs_betroffene. htm; Stand: 2. September 2004.
32. Leitlinien der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN). Schizophrenie. Kurzfassung. AWMF-Leitlinien-Register Nr. 038/009, in Überarbeitung zu S3-Leitlinie. http://leitlinien.net/.
33. Leucht S, Barnes TR, Kissling W, Engel RR, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
34. Mahmoud R, Engelhart L, Janagap C, Oster G, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. Clin Drug Invest 2004;24:275-86.
35. McIntyre R, Trakas K, Lin D, Balshaw R, et al. Risk of adverse events associated with antipsychotic treatment: Results from the Canadian national outcomes measurement study in schizophrenia (CNOMSS). 51st Annual Canadian Psychiatric Association Meeting, Montreal, 2001.
36. Menke R, Janssen B, Gaebel W. Mehr Kompetenz für schizophrene Patienten. Klinik und Poliklinik für Psychiatrie Psychotherapie der Heinrich-Heine-Universität/Rheinische Kliniken Düsseldorf: 20. Juni 2002. Projektbericht zum Kompetenznetz Schizophrenie in www.praxisnetz. multimedica.de; Stand: Oktober 2004.
37. National Institute for Clinical Excellence. Schizophrenia. Core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guideline, 1. December 2002.
38. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia. Can J Psychiatry 1991;36:239-45.
39. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsychotic treatment. Acta Psychiatr Scand 2000;407:83-6.
40. Otte C, Naber D. Compliance in der Therapie mit Neuroleptika, Antidepressiva und Lithium. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2001;44:14-9.
41. Remington GJ, Adams ME. Depot neuroleptic therapy: Clinical considerations. Can J Psychiatry 1995;40:5-12.
42. Rettenbacher MA, Burns T, Kemmler G, Fleischhacker WW. Schizophrenia: attitudes of patients and professional carers towards the illness und antipsychotic medication. Pharmacopsychiatry 2004;37:103-9.
43. Salize HJ, Rössler W. The cost of comprehensive care of people with schizophrenia living in the community. A cost evaluation from a German catchment area. Br J Psychiatry 1996;169:42-8.
44. Salize HJ. Die Kosten der Schizophrenie - was wissen wir (nicht)? Psychiatr Praxis 2001;28(Sonderheft 1):21-8.
45. Schwabe U, Paffrath D (Hrsg.). Arzneiverordnungsreport 2004. Aktuelle Duten. Kosten. Trends und Kommentare. Berlin. Heidelberg. New York: Springer-Verlug. 2004:787-93.
46. Swainston HT, Goa KL. Long-acting risperidone. A review of its use in schizophrenia. CNS Drugs 2004;18:113-32.
47. Tollefson GD, Beasly CM, Tran PV, Street JS. et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 2002;154:457-65.
48. Valenstein M, Copeland LA, Blow FC, McCarthy JF, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40: 630-9.
49. Weiden PJ, Ross R. Why do patients stop their antipsychotic medications? A guide for family and friends. J Psychiatric Pract 2002;8: 413-6.
50. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among Californian medicaid patients with schizophrenia. Psychiatr Serv 2004;55: 886-91.
51. Wirshing DA, Wirshing WC, Kysar L, Berisford AM, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.